Latest Breaking News On - ஃபார்டம் நிதி மேலாண்மை இன்க் - Page 10 : comparemela.com

BriaCell Announces Closing of US$25 Million Public Offering BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today closed its previously announced underwritten public offering in the United States. The Company offered 4,852,353 common units at a public offering price of US$4.25 per unit, consisting of one share of common stock and one warrant to purchase one share of common stock and … BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”) a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today closed its previously announced underwritten public offering in the United States. The Company offered 4,852,353 common units at a public offering price of US$4.25 per unit, consisting of one share of common stock and one warrant to purchase one share of common stock (“Warrant”), and 1,030,000 pre-f

New yorkUnited statesWilliamv williamsExchange commissionCorporate developmentFordham financial management incRegulation services providerVenture exchangeBriacell therapeutics corpBriacell therapeuticsPre funded warrantsNasdaq capital marketFordham financial managementபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்பரிமாற்றம் தரகு